BLINK15 is a BBB-penetrant CDK5 inhibitor. BLINK15 lowers CDK5 activity for both complexes CDK5/p35 (IC50 = 29.34 nM) and CDK5/p25 (IC50 = 12.08 nM). BLINK15 offers anti-diabetic and neuroprotective benefits. BLINK15 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice.

BLINK11 is a BBB-penetrant CDK5 inhibitor. BLINK11 lowers CDK5 activity for both complexes CDK5/p35 (IC50 = 17.09 nM) and CDK5/p25 (IC50 = 14.69 nM). BLINK11 offers anti-diabetic and neuroprotective benefits. BLINK11 lowers blood glucose, enhances cognition, and reduces neurodegeneration in T2D mice.

BJP-07-017-3 is the inhibitor for proline cis trans isomerase (Pin1) with an IC50 of 9 nM. BJP-07-017-3 forms covalent bond with Cys113 of Pin1, induces conformational changes in Pin1, reduces its stability, and leads to a proteasome-dependently degradation.

Biphenomycin A (LL-AF283α) is a cyclic peptide antibiotic that can be found in Streptomyces griseorubiginosus 43708. It has antibacterial activity and can be used in research in the field of anti-infection.

Biotin-PEG5-Mal is a PROTAC linker, belonging to the PEG class. It can be used for the synthesis of PROTAC molecules.

BI 1181181 MZ is a potent and selective BACE1 inhibitor. BI 1181181 MZ can be used in the research for Alzheimer’s disease.

BGC4 is a biphenyl-based gold(III) complex. BGC4 inhibits human recombinant thioredoxin reductase (TrxR) with an IC50 of 10.7 μM, exhibits cytotoxicity (IC50 for MDA-MB-231 is 5.4 μM), and induces apoptosis. BGC4 exhibits antitumor efficacy in mouse models.

Betulin ditosylate is a derivative of Betulin. Betulin is a sterol regulatory element-binding protein (SREBP) inhibitor.

Bestatin-amide-PEG3-CH2-acid is an E3 ligase ligand-linker conjugate. Bestatin-amide-PEG3-CH2-acid can be used to synthesize PROTAC RAR Degrader-1. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.

Benapenem is a carbapenem-type agent that belongs to the broad-spectrum β-lactam antibiotic class.

BC13 is a CDK6/BRD4 inhibitor with the IC50 values of 234 nM and 36 nM for CDK6 and BRD4, respectively. BC13 shows antiproliferative activity and induces cell apoptosis and DNA damage. BC13 increases in ROS levels.

BBDDL2204 (compound 13) is a potent and selective EZH2 covalent inhibitor. BBDDL2204 inhibits EZH2Y641F with an IC50 of 2.5 nM.

BB-Cl-Amidine TFA is a peptidylarginine deminase (PAD) inhibitor.

BAY-593 (hydrochloride) is an orally active GGTase-I inhibitor. BAY-593 (hydrochloride) can block YAP1/TAZ signaling in animals and has antitumor activity.

BAY-277 is a METAP2 degrader, with IC50 values of 5.8 nM and 5.9 nM for hMETAP2 and mMETAP2, respectively.

BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes.

Bactobolin hydrochloride (Compound 1) is an antibiotic, which inhibits Escherichia coli, Salmonella, Shigella, Staphylococcus and Bacillus subtilis, with MICs of 0.3-6.25 μg/mL. Bactobolin hydrochloride exhibits antitumor efficacy against leukemia, with a LD50 value of 6.25-12.5 mg/kg.

AX-53802 is a ferroptosis inducer targeting GPX4 with an IC50 of 0.34 µM. AX-53802 forms a covalent bond with GPX4, initiating membrane translocation directly upon binding. AX-53802 and FAK/Src inhibitors promotes cell death. AX-53802 can be used for cancer study.

AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).

AUPF02, a 5-arylurea uracil derivative, is a potent anti-breast cancer agent, with an IC50 of 23.4 µM for MCF-7 cells.

ATUX-8385 is a potent PP2A activator. ATUX-8385 binds to PR65 subunit. ATUX-8385 has the potential for the research of cancers and chronic conditions such as Alzheimer’s disease and chronic obstructive pulmonary disease.

Atebimetinib is an inhibitor for MEK tyrosine kinase and exhibits antineoplastic activity.

ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa.

ASTX295 is a selective mouse double minute 2 (MDM2) antagonist with an IC50 value of <1 nM. ASTX295 specifically blocks the interaction between MDM2 and p53, reactivating wild-type (WT) TP53, and then inducing the expression of related transcriptional targets, leading to cell death and cell cycle arrest. ASTX295 is promising for research of lymphoid malignancies, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and T-cell lymphoma.

Aspochracin is an insecticidal substance and a cyclotripeptide which can be extracted from Aspergillus ochraceus. Aspochracin can be utilized in insecticidal research.

AS-254s is the inhibitor for absent, small, or homeotic-like 1 protein (ASH1L) with an IC50 of 94 nM (FP assay). AS-254s exhibits antiproliferative activity against MLL1-rearranged leukemic cells with GI50 <1 μM. AS-254s induces the differentiation of MLL1-r leukemic cell.

Aplysin is a brominated sesquiterpene with an isoprene backbone that exhibits hepatoprotective, immunomodulatory, and antitumor activities. Aplysin effectively prevents spontaneous pancreatic necrosis and inflammatory responses in NOD mice.

APL-1091 (Mal-Exo-EEVC-MMAE) is part of a Drug-linker conjugate for ADC. APL-1091 contains a Mal-Exo-EEVC linker and MMAE (Microtubule inhibitor). APL-1091 can be used for ADC synthesis.

API32 is a potent Pin1 inhibitor. API32 interactes with the Pin1 PPIase domain. API32 inhibits cell proliferation and migration. API32 has the potential for the research of hepatocellular carcinoma (HCC).

APD-94 is a dual inhibitor targeting tubulin and Bmi-1. APD-94 interfers tubulin normal polymerization. APD-94 suppresses the expression of Bmi-1. APD-94 causes cell cycle arrest at the G2/M phase in cancer cells and induces apoptosis, thus inhibiting cancer cell proliferation. APD-94 represses the growth of HT29 cell xenografts in NOD/SCID mice. APD-94 can be used for colorectal cancer study.